ViiV Healthcare, the global specialist HIV company majority-owned by GSK plc, announced landmark clinical, real-world, and pipeline data presented at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. Headlining the presentation, 96-week results from the Phase III LATA trial demonstrated that Cabenuva (cabotegravir + rilpivirine) dosed every two months is superior to daily oral therapy in virologically suppressed adolescents aged 12 to 19. The study showed confirmed viral rebound occurred in just 0.9% of adolescents receiving Cabenuva compared to 6.4% on daily oral treatment, with 94% reporting that long-acting injections were much easier to manage than daily pills.
Reinforcing these findings in adult populations, real-world evidence from the US-based OPERA cohort of nearly 6,800 adults showed Cabenuva maintained virologic suppression comparable to daily oral BIC/FTC/TAF, with low confirmed virologic failure rates of 1% and 2%, respectively. Additionally, six-month follow-up data from the Phase I CLARITY study revealed a significantly more favorableinjection experience for long-acting cabotegravir (CAB LA) compared to lenacapavir (LEN) after a single dose. Seventy percent of participants rated the CAB LA experience as highly acceptable versus 37% for LEN, with CAB LA demonstrating far lower rates of persistent injection-site nodules (20% vs. 90%). Real-world insights from CAPTIVATE and PrEPFACTS further highlighted strong preference (97%) and high adherence (89%) for CAB LA (Apretude) for HIV prevention.
Advancing its next-generation long-acting pipeline, ViiV Healthcare also shared baseline demographics from the Phase IIb EXTEND 4M trial evaluating a novel intramuscular cabotegravir formulation administered three times per year. Together, these milestone data underscore ViiV Healthcare’s commitment to expanding access, improving patient adherence, and defining the future of HIV treatment and prevention.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
